Literature DB >> 16439564

APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count.

Soo-Jin Cho1, Henning Drechsler, Ryan C Burke, Max Q Arens, William Powderly, Nicholas O Davidson.   

Abstract

APOBEC3F and APOBEC3G (hA3F and hA3G) are part of an innate mechanism of antiretroviral defense. The human immunodeficiency virus type 1 (HIV-1) accessory protein Vif targets both proteins for proteasomal degradation. Using mRNA from peripheral blood mononuclear cells of 92 HIV-infected subjects not taking antiretroviral therapy and 19 HIV-uninfected controls, we found that hA3F (P < 0.001) and hA3G (P = 0.016) mRNA levels were lower in HIV-infected subjects and were positively correlated with one another (P = 0.003). However, we found no correlation in the abundance of either hA3F or hA3G mRNA with either viral load or CD4 counts in HIV-infected subjects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439564      PMCID: PMC1367163          DOI: 10.1128/JVI.80.4.2069-2072.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.

Authors:  Andrew Mehle; Bettina Strack; Petronela Ancuta; Chengsheng Zhang; Mark McPike; Dana Gabuzda
Journal:  J Biol Chem       Date:  2003-12-13       Impact factor: 5.157

2.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

3.  The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.

Authors:  Silvestro G Conticello; Reuben S Harris; Michael S Neuberger
Journal:  Curr Biol       Date:  2003-11-11       Impact factor: 10.834

Review 4.  Retroviral restriction by APOBEC proteins.

Authors:  Reuben S Harris; Mark T Liddament
Journal:  Nat Rev Immunol       Date:  2004-11       Impact factor: 53.106

5.  Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection.

Authors:  J M Raboud; J S Montaner; B Conway; L Haley; C Sherlock; M V O'Shaughnessy; M T Schechter
Journal:  J Infect Dis       Date:  1996-07       Impact factor: 5.226

6.  APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.

Authors:  Mark T Liddament; William L Brown; April J Schumacher; Reuben S Harris
Journal:  Curr Biol       Date:  2004-08-10       Impact factor: 10.834

7.  Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.

Authors:  Yong-Hui Zheng; Dan Irwin; Takeshi Kurosu; Kenzo Tokunaga; Tetsutaro Sata; B Matija Peterlin
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Longitudinal HIV-1 RNA levels in a cohort of homosexual men.

Authors:  T R O'Brien; P S Rosenberg; F Yellin; J J Goedert
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-06-01

9.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

10.  Cytidine deamination of retroviral DNA by diverse APOBEC proteins.

Authors:  Kate N Bishop; Rebecca K Holmes; Ann M Sheehy; Nicholas O Davidson; Soo-Jin Cho; Michael H Malim
Journal:  Curr Biol       Date:  2004-08-10       Impact factor: 10.834

View more
  41 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.

Authors:  Craig Pace; Jean Keller; David Nolan; Ian James; Silvana Gaudieri; Corey Moore; Simon Mallal
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  APOBEC3G and HIV-1: strike and counterstrike.

Authors:  Vanessa B Soros; Warner C Greene
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

Review 4.  HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.

Authors:  Viviana Simon; David D Ho; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

5.  APOBEC3G and HIV-1: strike and counterstrike.

Authors:  Vanessa B Soros; Warner C Greene
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

Review 6.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

7.  Natural Single-Nucleotide Variations in the HIV-1 Genomic SA1prox Region Can Alter Viral Replication Ability by Regulating Vif Expression Levels.

Authors:  Masako Nomaguchi; Naoya Doi; Yosuke Sakai; Hirotaka Ode; Yasumasa Iwatani; Takamasa Ueno; Yui Matsumoto; Yasuyuki Miyazaki; Takao Masuda; Akio Adachi
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

8.  In vivo HIV-1 hypermutation and viral loads among antiretroviral-naive Brazilian patients.

Authors:  Mariana Leão de Lima-Stein; Wagner Tadeu Alkmim; Maria Clara de Souza Bizinoto; Luis Fernandez Lopez; Marcelo Nascimento Burattini; Juliana Terzi Maricato; Leila Giron; Maria Cecília Araripe Sucupira; Ricardo Sobhie Diaz; Luiz Mario Janini
Journal:  AIDS Res Hum Retroviruses       Date:  2014-08-25       Impact factor: 2.205

9.  Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif.

Authors:  Kara G Lassen; Silke Wissing; Michael A Lobritz; Mario Santiago; Warner C Greene
Journal:  J Biol Chem       Date:  2010-07-12       Impact factor: 5.157

10.  Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection.

Authors:  Shamman Sewram; Ravesh Singh; Emil Kormuth; Lise Werner; Koleka Mlisana; S S Abdool Karim; Thumbi Ndung'u
Journal:  J Infect Dis       Date:  2009-06-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.